Cargando…

DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4

Chemoresistance cells have features similar to cancer stem cells. Elimination of these cells is an effective therapeutic strategy to clinically combat chemoresistance non-small cell lung cancer (NSCLC). Here, we demonstrate that Doublecortin-like kinase1 (DCLK1) is the key to developing chemoresista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panneerselvam, Janani, Mohandoss, Priyanga, Patel, Ravi, Gillan, Hamza, Li, Michael, Kumar, Kirtana, Nguyen, DangHuy, Weygant, Nathaniel, Qu, Dongfeng, Pitts, Kamille, Lightfoot, Stanley, Rao, Chinthalapally, Houchen, Courtney, Bronze, Michael, Chandrakesan, Parthasarathy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321820/ https://www.ncbi.nlm.nih.gov/pubmed/32637578 http://dx.doi.org/10.1016/j.omto.2020.05.012

Ejemplares similares

Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2014)

Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2016)

Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells
por: Chandrakesan, P, et al.
Publicado: (2016)

DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer
por: Sureban, Sripathi M., et al.
Publicado: (2013)

Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment
por: Cao, Zhiyun, et al.
Publicado: (2020)

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer
por: Qu, Dongfeng, et al.
Publicado: (2019)

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism
por: Sureban, Sripathi M., et al.
Publicado: (2015)

Dclk1(+) small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2015)

Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2017)

Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases
por: Ali, Naushad, et al.
Publicado: (2015)

DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma
por: Weygant, Nathaniel, et al.
Publicado: (2014)

Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments
por: Wu, Xiangyan, et al.
Publicado: (2020)

Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism
por: Panneerselvam, Janani, et al.
Publicado: (2021)

Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury
por: Sureban, Sripathi M., et al.
Publicado: (2015)

Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
por: Yarla, Nagendra Sastri, et al.
Publicado: (2020)

Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis
por: Qu, Dongfeng, et al.
Publicado: (2015)

Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism
por: Ali, Naushad, et al.
Publicado: (2013)

Correction: Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism
por: Ali, Naushad, et al.
Publicado: (2013)

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
por: Weygant, Nathaniel, et al.
Publicado: (2014)

Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
por: Christman, Emily M., et al.
Publicado: (2019)

Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity
por: Ding, Ling, et al.
Publicado: (2021)

Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells
por: Qu, Dongfeng, et al.
Publicado: (2015)

Bufalin Inhibits Tumorigenesis, Stemness, and Epithelial–Mesenchymal Transition in Colorectal Cancer through a C-Kit/Slug Signaling Axis
por: Ding, Ling, et al.
Publicado: (2022)

Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism
por: Ali, Naushad, et al.
Publicado: (2020)

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers
por: Sureban, Sripathi M., et al.
Publicado: (2019)

DCLK1 immunoreactivity in colorectal neoplasia
por: Gagliardi, Giuseppe, et al.
Publicado: (2012)

DCLK1 autoinhibition and activation in tumorigenesis
por: Cheng, Linna, et al.
Publicado: (2021)

Analysis of the clinical significance of DCLK1(+) colorectal cancer using novel monoclonal antibodies against DCLK1
por: Dai, Tianqi, et al.
Publicado: (2018)

Structural Basis of Inhibition of DCLK1 by Ruxolitinib
por: Jang, Dong Man, et al.
Publicado: (2021)

Structure-Guided Prediction of the Functional Impact of DCLK1 Mutations on Tumorigenesis
por: Carli, Annalisa L. E., et al.
Publicado: (2023)

Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19
por: Undi, Ram Babu, et al.
Publicado: (2022)

Pleiotropic effects of DCLK1 in cancer and cancer stem cells
por: Chhetri, Dibyashree, et al.
Publicado: (2022)

DCLK1 Variants Are Associated across Schizophrenia and Attention Deficit/Hyperactivity Disorder
por: Håvik, Bjarte, et al.
Publicado: (2012)

The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin
por: Galvan, Laurie, et al.
Publicado: (2018)

DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma
por: Lorenzo, Nevi, et al.
Publicado: (2021)

DCLK1 Inhibition Sensitizes Colorectal Cancer Cells to Radiation Treatment
por: Mohammadi, Chiman, et al.
Publicado: (2021)

Mechanistic and evolutionary insights into isoform-specific ‘supercharging’ in DCLK family kinases
por: Venkat, Aarya, et al.
Publicado: (2023)

Mechanistic and evolutionary insights into isoform-specific ‘supercharging’ in DCLK family kinases
por: Venkat, Aarya, et al.
Publicado: (2023)

Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1
por: Patel, Onisha, et al.
Publicado: (2021)

Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1's elimination during colon cancer development and progression
por: Roy, Badal Chandra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pbqvoprbcoumo99mpba4jh9tk4